Activity

lity and attenuate CVD disease risk.[This corrects the article DOI 10.1016/j.conctc.2020.100567.][This corrects the article DOI 10.1016/j.conctc.2020.100558.][This corrects the article DOI 10.1016/j.conctc.2020.100541.][This corrects the article DOI 10.1016/j.conctc.2020.100535.][This corrects the article DOI 10.1016/j.conctc.2020.100565.][This corrects the article DOI 10.1016/j.conctc.2020.100526.][This corrects the article DOI 10.1016/j.conctc.2020.100579.][This corrects the article DOI 10.1016/j.conctc.2020.100549.][This corrects the article DOI 10.1016/j.conctc.2020.100528.][This corrects the article DOI 10.1016/j.conctc.2020.100522.][This corrects the article DOI 10.1016/j.conctc.2020.100550.][This corrects the article DOI 10.1016/j.conctc.2020.100545.][This corrects the article DOI 10.1016/j.conctc.2020.100532.].[This corrects the article DOI 10.1016/j.conctc.2020.100627.][This corrects the article DOI 10.1016/j.conctc.2020.100621.][This corrects the article DOI 10.1016/j.conctc.2019.100398.][This corrects the article DOI 10.1016/j.conctc.2019.100366.][This corrects the article DOI 10.1016/j.conctc.2019.100316.][This corrects the article DOI 10.1016/j.conctc.2020.100605.][This corrects the article DOI 10.1016/j.conctc.2019.100363.][This corrects the article DOI 10.1016/j.conctc.2019.100336.][This corrects the article DOI 10.1016/j.conctc.2019.100327.][This corrects the article DOI 10.1016/j.conctc.2019.100365.][This corrects the article DOI 10.1016/j.conctc.2019.100376.][This corrects the article DOI 10.1016/j.conctc.2019.100344.][This corrects the article DOI 10.1016/j.conctc.2020.100607.][This corrects the article DOI 10.1016/j.conctc.2020.100592.][This corrects the article DOI 10.1016/j.conctc.2020.100612.].[This corrects the article DOI 10.1016/j.conctc.2019.100461.][This corrects the article DOI 10.1016/j.conctc.2019.100470.][This corrects the article DOI 10.1016/j.conctc.2019.100434.][This corrects the article DOI 10.1016/j.conctc.2019.100415.][This corrects the article DOI 10.1016/j.conctc.2019.100491.][This corrects the article DOI 10.1016/j.conctc.2019.100452.][This corrects the article DOI 10.1016/j.conctc.2019.100433.][This corrects the article DOI 10.1016/j.conctc.2019.100416.][This corrects the article DOI 10.1016/j.conctc.2019.100467.][This corrects the article DOI 10.1016/j.conctc.2019.100460.][This corrects the article DOI 10.1016/j.conctc.2019.100412.][This corrects the article DOI 10.1016/j.conctc.2019.100404.][This corrects the article DOI 10.1016/j.conctc.2019.100495.][This corrects the article DOI 10.1016/j.conctc.2019.100457.][This corrects the article DOI 10.1016/j.conctc.2019.100432.].[This corrects the article DOI 10.1016/j.conctc.2018.09.005.][This corrects the article DOI 10.1016/j.conctc.2018.08.011.][This corrects the article DOI 10.1016/j.conctc.2018.01.006.][This corrects the article DOI 10.1016/j.conctc.2018.03.007.][This corrects the article DOI 10.1016/j.conctc.2018.04.003.][This corrects the article DOI 10.1016/j.conctc.2018.03.008.][This corrects the article DOI 10.1016/j.conctc.2018.07.002.][This corrects the article DOI 10.1016/j.conctc.2018.07.001.][This corrects the article DOI 10.1016/j.conctc.2018.01.007.][This corrects the article DOI 10.1016/j.conctc.2018.05.010.][This corrects the article DOI 10.1016/j.conctc.2018.07.007.][This corrects the article DOI 10.1016/j.conctc.2018.08.009.][This corrects the article DOI 10.1016/j.conctc.2019.100511.][This corrects the article DOI 10.1016/j.conctc.2018.05.013.][This corrects the article DOI 10.1016/j.conctc.2018.05.002.].

Type 2 diabetes (T2D) is the leading non-communicable disease worldwide and is associated with several microvascular and macrovascular complications. Individuals with T2D are more prone to acquiring selected types of infections and are more susceptible to complications due to these infections. This study aimed to evaluate the relationship between T2D and COVID-19 in the community setting.

This was a single-center retrospective analysis that included 147 adult patients with laboratory-confirmed COVID-19 admitted to a community hospital. Demographics, medical history, symptoms and signs, laboratory findings, complications during the hospital course, and treatments were collected and analyzed. The Kaplan-Meier method was used to describe the probability of intubation in patients with T2D as compared with patients without T2D. The hazard ratio for intubation in the survival analysis was estimated using a bivariable Cox proportional-hazards model.

Of 147 patients, 73 (49.7%) had a history of T2D. Patients with T2D had higher requirement of ICU admission (31.5% vs 12.2%; p=.004), higher incidence of ARDS (35.6% vs 16.2%, p=.007), higher rates of intubation (32.9% vs 12.2%, p=.003), and higher use neuromuscular blocking agents (23.3% vs 9.5%, p=.02). In the survival analysis at 28 days of follow-up, patients with T2D showed an increased hazard for intubation (HR 3.00; 95% CI, 1.39 to 6.46).

In our patient population, patients with COVID-19 and T2D showed significantly higher ARDS incidence and intubation rates. The survival analysis also showed that after 28 days of follow-up, patients with T2D presented an increased risk for shorter time to intubation.

In our patient population, patients with COVID-19 and T2D showed significantly higher ARDS incidence and intubation rates. The survival analysis also showed that after 28 days of follow-up, patients with T2D presented an increased risk for shorter time to intubation.The recent pandemic, COVID-19, is caused by a novel coronavirus, SARS-CoV-2, with elusive origin. SARS-CoV-2 infects mammalian cells via ACE2, a transmembrane protein. Therefore, the conservation and expression patterns of ACE2 may provide valuable insights into tracing the carriers of SARS-CoV-2. GSK269962A In this work, we analyzed the conservation of ACE2 and its expression pattern among various mammalian species that are close to human beings. We show that mammalian ACE2 gene is deeply conserved at both DNA and peptide levels, suggesting that a broad range of mammals can potentially host SARS-CoV-2. We further report that ACE2 expression in certain human tissues are consistent with clinical symptoms of COVID-19 patients. Furthermore, we have built the first atlas of ACE2 expression in various common mammals, which shows that ACE2 expresses in mammalian tissues in a species-specific manner. Most notably, we observe exceptionally high expression of ACE2 in external body parts of cats and dogs, suggesting that these household pet animals could be vulnerable to viral infections and/or may serve as intermediate hosts, thus yielding novel insights into the transmission of SARS-CoV-2.